Veracyte (NASDAQ:VCYT) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical Comparison

Veracyte (NASDAQ:VCYT) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Veracyte and Lakefront Biotherapeutics American Depositary Shares”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90 million	6.08	$66.35 million	$1.41	30.16
Lakefront Biotherapeutics American Depositary Shares	$990.57 million	1.90	$363.05 million	($1.41)	-20.21

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Veracyte. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Veracyte and Lakefront Biotherapeutics American Depositary Shares, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	2	6	2	2.82
Lakefront Biotherapeutics American Depositary Shares	0	7	1	1	2.33

Veracyte presently has a consensus price target of $54.33, suggesting a potential upside of 27.75%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $30.67, suggesting a potential upside of 7.64%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Risk & Volatility

Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Profitability

This table compares Veracyte and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Veracyte beats Lakefront Biotherapeutics American Depositary Shares on 11 of the 15 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.